Market Research Report
Rabies - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||219865|
|Published||Content info||96 Pages
Delivery time: 1-2 business days
|Rabies - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 96 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H1 2020, provides an overview of the Rabies (Infectious Disease) pipeline landscape.
Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 3, 5, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 1 molecules, respectively.
Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.